Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHPA on NDIs

This article was originally published in The Tan Sheet

Executive Summary

"A single NDI notification may be submitted for more than one dietary supplement that contains the NDI that is the subject of the notification," AHPA maintains in a Feb. 24 addendum to previously submitted comments. "Dietary supplements that contain up to 100 mg per serving of the NDI; that are in the form of a capsule or tablet; and that are recommended to be used by adults over the age of 18 in a manner that limits daily consumption of the NDI to not more than 1,000 mg per day for up to 6 months" is a statement that would reduce the need for redundant filings, the trade group suggests. In this vein, manufacturers, marketers and distributors who sell supplements that conform to the dose and use parameters outlined in the notifications should not have to file their own NDI submissions...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS097885

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel